Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | ALK F1174V |
Therapy | Irinotecan + Repotrectinib + Temozolomide |
Indication/Tumor Type | neuroblastoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ALK F1174V | neuroblastoma | predicted - sensitive | Irinotecan + Repotrectinib + Temozolomide | Preclinical - Pdx | Actionable | In a preclinical study, combination treatment with Augtyro (repotrectinib), Camptosar (irinotecan), and Temodar (temozolomide) resulted in inhibition of tumor growth in a patient-derived xenograft (PDX) model of neuroblastoma harboring ALK F1174V (PMID: 34482287). | 34482287 |
PubMed Id | Reference Title | Details |
---|---|---|
(34482287) | Translational Strategies for Repotrectinib in Neuroblastoma. | Full reference... |